Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big-Name Drugs Try New Roles In Rheumatism

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly’s Cymbalta performs well in major osteoarthritis trial.

You may also be interested in...



Lilly Submits Cymbalta For Chronic Pain

If approved for fibromyalgia and chronic pain, drug label would include six indications.

FDA Clears BMS’ Orencia In Juvenile Arthritis

Second indication comes with news of Repligen settlement.

Abbott’s Humira Approved For Juvenile Idiopathic Arthritis

Tumor necrosis factor inhibitor an important option to Wyeth’s Enbrel, Abbott tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS067908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel